SMARCA4 and acute myeloid leukemia: ACBI1 demonstrated anti-proliferative effects and induced cell death caused by SMARCA2 depletion in SMARCA4 mutant cancer cells, along with impacts in AML cells reliant on SMARCA4 ATPase activity.